| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | Acarix AB: Acarix responds to G-BA decision on reimbursement in the German market | 134 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that G-BA reached a negative decision on the possibility for CADScor System to receive reimbursement... ► Artikel lesen | |
| ACARIX Aktie jetzt für 0€ handeln | |||||
| 21.08. | Acarix AB: Acarix Reports Significant Progress Toward Fixed Reimbursement | 157 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another milestone on its path toward fixed reimbursement... ► Artikel lesen | |
| 21.08. | Acarix AB: Acarix Publishes Interim Report, January - June 2025 | 138 | GlobeNewswire (Europe) | Malmö, Sweden (Aug. 21, 2025) - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the second quarter and first half of 2025. The... ► Artikel lesen | |
| 28.07. | Acarix AB: Acarix achieves new Fixed U.S. reimbursement milestone for CADScor at $300.00 USD | 216 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that a second payer has agreed to provide fixed reimbursement of $300 for the CADScor®... ► Artikel lesen | |
| 08.07. | Acarix AB: Acarix Enters MENA Region with First Major Order, Expanding Global Presence | 250 | GlobeNewswire (Europe) | Malmö, Sweden - July 8, 2025 - Acarix, a global pioneer in AI-driven and acoustics-based cardiac diagnostics, is proud to announce its first order in the Middle East and North Africa (MENA) region.... ► Artikel lesen | |
| 26.06. | Acarix AB: Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor System in U.S. Emergency Departments | 239 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics - Open demonstrating that the CADScor®... ► Artikel lesen | |
| 16.06. | Acarix AB: Acarix Achieves First Fixed U.S. Reimbursement Milestone for CADScor at $300.00 USD | 227 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix a global leader in AI and acoustics-based cardiac diagnostics, is pleased to announce that the first payor has agreed to provide fixed reimbursement for the CADScor® System at... ► Artikel lesen | |
| 12.05. | Acarix AB: Acarix Publishes Interim Report, January - March 2025 | 324 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the first quarter of 2025. The report highlights continued growth in the U.S.... ► Artikel lesen | |
| 13.02. | Acarix Publishes Year-End Report 2024 - Sales and revenue for the CADScor System and patches are surging amid ongoing U.S. expansion efforts | 347 | PR Newswire | OKLAHOMA CITY, Feb. 13, 2025 /PRNewswire/ -- Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2024 year-end financial results. "The company continues... ► Artikel lesen | |
| 07.11.24 | Acarix AB: Acarix Publishes Third Quarter 2024 Report | 234 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its financial results for the third quarter of 2024. The company has made significant progress toward operational... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 47,090 | +1,29 % | Fresenius Medical Care AG: Ein langsames, aber stetiges drittes Quartal erwartet. Herabgestuft auf Halten. | Fresenius Medical Care (FME) wird seine Ergebnisse für das dritte Quartal 2025 am 4. November veröffentlichen. Nach gemischten Resultaten im ersten Halbjahr mit lediglich +2 % Umsatzwachstum yoy und... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 45,860 | -2,88 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec auf "Underweight" mit einem Kursziel von 35,10 Euro belassen. Anchal Verma sieht in einer am Freitag vorliegenden... ► Artikel lesen | |
| ECKERT & ZIEGLER | 17,550 | -0,62 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| UNITEDHEALTH | 312,00 | +0,10 % | UnitedHealth: Zu viel Optimismus? | Die Aktie des größten US-amerikanischen Krankenversicherers hat sich in den zurückliegenden Wochen zwar deutlich von den Mehrjahrestiefs nach oben lösen können. Allerdings notiert der Titel immer noch... ► Artikel lesen | |
| HIMS & HERS HEALTH | 42,000 | +0,17 % | HIMS & HERS: Schon wieder aufnehmen? | Die Aktie der US-Vertriebsplattform für bestimmte Medikamente verlor am Freitag 15,8 % und sogar fast 24 % gegenüber dem Zwischenhoch vom Donnerstag. Wesentlicher Auslöser war Donald Trump mit seinem... ► Artikel lesen | |
| BICO GROUP | 2,034 | -0,49 % | BICO Group AB: Maria Rankka appointed Board Chair of BICO Group AB | The Board of Directors has with immediate effect among its members elected Maria Rankka to serve as Board Chair of BICO Group AB, until a new chair has been elected by the shareholders' meeting. Maria... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,030 | +2,74 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
| SPINEWAY | 0,144 | -5,01 % | Spineway: Revenue growth in the third quarter | Ecully, October 14, 2025 - 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Announces Voting Results from Special Meeting of Stockholders | -- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales... ► Artikel lesen | |
| UNIDOC HEALTH | 0,119 | +0,68 % | UniDoc Health Corp.: UniDoc Announces Amended LIFE Offering | THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)... ► Artikel lesen | |
| VERU | 3,790 | +2,43 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| CLARIANE | 4,484 | +0,04 % | Jetzt bewerben! Korian Stiftungsaward für Vielfalt und Respekt in der Pflege 2026 | München (ots) - Die gemeinnützige Korian Stiftung für Pflege und würdevolles Altern schreibt zum sechsten Mal den Korian Stiftungsaward für Vielfalt und Respekt in der Pflege aus. Mit dem Preis zeichnet... ► Artikel lesen | |
| SENSEONICS | 0,349 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.10.2025 | Das Instrument TKA DE0007500001 THYSSENKRUPP AG O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 17.10.2025 und ex Kapitalmassnahme am 20.10.2025 The instrument TKA DE0007500001 THYSSENKRUPP AG O.N.... ► Artikel lesen | |
| VIROMED MEDICAL | 3,540 | -0,56 % | EQS-DD: Viromed Medical AG: Uwe Perbandt, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.10.2025 / 18:01... ► Artikel lesen | |
| BONESUPPORT | 21,560 | -0,09 % | Bonesupport Holding AB: Bonesupport Holding AB (publ) - Publishes Q3 2025 Interim Report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2025.
"Solid growth and new clinical... ► Artikel lesen |